Actively engaged with Terumo in Virtue SAB partnership restructuring discussions.
UPMC Heart and Vascular Institute in central Pennsylvania has treated its first patient with a new therapy.
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical innovation company accelerating high-impact technologies ...
Summary: The use of balloon angioplasty with or without coronary artery stenting is limited by the phenomenon of in-stent restenosis (ISR). Until very recently, most efforts to overcome ISR had ...
Braun) DEB (based on PACCOCATH® technology [Bayer//Medrad]) compared with the TAXUS Liberté DES for treatment of ISR in native coronary arteries (n = 131 patients, reference diameter 2.5 mm ...
TCT 320: Dynamic Coronary Roadmap in Occluded Vessel Angioplasty in STEMI: Does It Still Reduce the Contrast Load: A Randomized Trial Subanalysis Receive the the latest news, research, and ...
to commence a pivotal clinical trial for its Prevail coronary paclitaxel drug-coated balloon (DCB). This trial is aimed at treating in-stent restenosis (ISR) and de novo small vessel disease.
Research Question: Are paclitaxel-coated balloons (PCBs) superior to uncoated balloons (UCBs) in terms of safety and efficacy for the treatment of coronary in-stent restenosis (ISR)? Aims: ...
Philips Laser System – Nexcimer supports over seven coronary vascular ranging from chronic total occlusions and a variety of different lesion types. It is the only system compatible with catheters ...
Simplifying coronary and peripheral atherectomy and lead ... compatible with catheters that have Level I clinical data for ISR (in-stent restenosis) atherectomy and the only to support lead ...